Browsing by Author "Oruc S."
Now showing 1 - 5 of 5
Results Per Page
Sort Options
Item The effects of magnesium sulphate on postoperative analgesia; [Magnezyum sulfatin postoperatif analjeziye etkileri](2000) Tekin I.; Erbuyun K.; Oruc S.; Toprak V.; Alincak H.It has been suggested that magnesium with its calcium channel blocking and NMDA antagonist properties could play a role in prevention and treatment of pain. We assessed the effect of perioperative IV magnesium sulfate on the early period of postoperative analgesia. ASA I or II class, at least graduated from secondary school, 30 patients, undergoing elective abdominal hysterectomy with TIVA (total intravenous anaesthesia), received standard premedication. We added saline (group I, n:15) or 15 % MgS04 (group II, n:15), 15 mL IV bolus after induction agents and 3 mL/h IV infusion at the end of the postoperative 6th hour. PCA (patient controlled analgesia) with fentanyl was used for postoperative analgeesia. Peroperative hemodynamic data, total propofol, fentanyl and vecuronium doses are noted. VAS (visuel analog scale) was used to assess postoperative pain and sedation scale for sedation assessment in postoperative 30. minutes and 2-4-6. hours. Determination of serum magnesium-concentration were obtained before the start Of the intravenous study drug treatment and after the end of the infusion. There were no differences in demographic data, ASA classification, duration of surgery, intraoperatif total propofol, fentanyl and vecuronium doses between two groups. Postoperative demand, delivery and total fentanyl levels were higher in group I (p<0.05). VAS and SS were similar in two groups. At the end of the infusion serum magnesium concentrations were higher than preoperative values in group II (p<0.05). In this study we found that magnesium-reduces postoperative analgesic requirements without adverse effects. In conclusion, magnesium is a good adjuan analgesic agent and will gain a popularity in the early future with new studies.Item The concentration of insulin-like growth factor-1 and insulin-like growth factor-binding protein-3 in maternal sera during pregnancy with normal and growth retarded fetuses; [Normal ve yetersiz fetal gelisim gosteren gebelerde gebelik suresince serum insulin benzeri buyume faktoru-1 (IGF-1) ve insulin benzeri buyume faktoru baglayici protein-3 (IGFBP-3) konsantrasyonlari](2000) Lacin S.; Oruc S.; Kuscu K.; Ersoy B.; Tansug N.; Uyanik B.S.; Yildirim Y.; Koyuncu F.Objective: To determine the concentrations of insulin-like growth factor-1 and insulin-like growth factor binding protein-3 in maternal sera of pregnancies with normal and growth retarded fetuses and investigate the relationship between these substances and fetal growth. Materials and Methods: Blood samples of 148 pregnant women were collected at 14-16 and 30-31 weeks and during delivery. Also cord blood samples were obtained during delivery. For the determination of IGF-1 and IGFBP-3, double-sided IRMA method was used. Infants were divided into two groups as normal and growth retarded fetuses based upon their patterns of growth using the percentile curves and the serum levels were compared. Correlation analysis and Mann-Whitney U test were used as statistical calculations. Results: Both IGF-1 and IGFBP-3 levels increased while approaching term in all pregnant women. In growth retarded cases, maternal IGF-1 levels were found to be significantly lower than pregnancies with normal fetuses (p< 0.005), but maternal IGFBP-3 levels were not different between two groups. IGF-1 levels in cord blood during delivery were not different while IGFBP-3 levels were significantly higher in growth retarded fetuses. Conclusion: Our study did not support the hypothesis that fetal growth retardation is due to IGF-1 deficiency. High binding protein levels may cause a relative free IGF-1 deficiency, but the levels of binding protein is probably secondary to metabolic changes or placental insufficiency. Low levels of IGF-1 and high levels of binding proteins implies the necessity of further investigation of placental transfer.Item Sexual life following total abdominal hysterectomy(2005) Kuscu N.K.; Oruc S.; Ceylan E.; Eskicioglu F.; Goker A.; Caglar H.Aim: The goal of this study was to evaluate the effect of total abdominal hysterectomy (TAH) on sexual lives of patients in the postoperative period. Materials and methods: Eighty-six patients who accepted to participate a phone-questionnaire were recruited in the study after TAH or TAH + BSO. They were asked about sexual desire, pain during sexual intercourse, frequency and satisfaction of sexual intercourse at pre- and postoperative periods, and loss of "feeling a woman" in the postoperative period. Sexual desire, pain during sexual intercourse, loss of "feeling a woman" questions were answered as "yes" or " no", number of weekly sexual intercourse was recorded, and satisfaction was graded as no = 0, mild = 1 and complete = 2 points. Results: While sexual desire and frequency were found to be significantly lower (p=0.026 and p=0.01 respectively), no difference was noted in dyspareunia and satisfaction. When the patients were divided into two groups according to the presence of endogenous or exogenous estrogen, no difference was seen between the two groups in the postoperative period. Conclusion: We concluded that the effect of TAH or TAH+BSO operations were mainly on sexual desire and the number of weekly intercourse, and estrogen in the postoperative period did not make any difference between the two groups. © Springer-Verlag 2004.Item Assessment of mammographic density changes on plain film mammograms in postmenopausal women on hormone replacement therapy(2006) Orguc S.; Goktan C.; Ovali G.Y.; Karaer O.; Oruc S.Background & objectives: Mammographic screening is an effective tool for the early detection of breast cancer. Hormone replacement therapy (HRT) has been shown to increase mammographic density and thus may hinder early detection of small tumours. We undertook this study to determine and compare the frequency and degree of change in mammographic density in postmenopausal women in HRT using two different methods: the classical Wolfe classification and a new semiquentitative method, which we named as the comparison wheel. Methods: This study included 285 women, 206 under hormone treatment, and 79 control subjects. All women underwent baseline mammographic study before the beginning of treatment. Mean interval of the follow up mommograms was 16 months. The methods were compared in evaluating the effects of three types of hormone therapies on mammographic density. Results: The frequency of change was only significant in the combined hormone replacement group when Wolfe classification was used. However, the frequency of increase in density (estrogen group 21%, combined therapy group 42%, tibolone group 28%) was markedly higher when the comparison wheel was used. The inter-rater Kappa value was calculated as 0.977 for the first and 0.957 for the second readings of the two radiologists for the comparison wheel, and 0.973 and 0.968 for the Wolfe classification. The intra-rater Kappa values were determined as 0.972 and 0.957 for the first and and 0.963 and 0.926 for the second radiologist for comparison wheel and Wolfe classification respectively. Interpretation & conclusion: Our findings indicate that the estimated increase of mammographic density depends on the selected hormone regimen, as well as the method of evaluation. The comparison wheel is a semiquantitative method of evaluating changes of mammographic density and is sensitive and reproducible with high inter- and intra-rater Kappa values. This method can be used as an alternative for comparison of digital mammographic applications in the future.Item A comparative study of the effect of raloxifene and gosereline on uterine leiomyoma volume changes and estrogen receptor, progesterone receptor, bcl-2 and p53 expression immunohistochemically in premenopausal women(Elsevier Ireland Ltd, 2007) Baytur Y.B.; Ozbilgin K.; Cilaker S.; Lacin S.; Kurtul O.; Oruc S.; Koyuncu F.M.Objective: To compare the mechanism of action of raloxifene and gosereline induced shrinkage of leiomyomas via estrogen receptor, progesterone receptor, bcl-2 and p53 expression immunohistochemically. Study design: Thirty-two premenopausal women affected by uterine leiomyomas were randomized into two equal groups. Group A was treated with gosereline (3.6 mg subcutaneous injection monthly) and group B was treated with raloxifene (60 mg daily per os) for 3 months before undergoing surgery. At entry and at the end of the treatment the leiomyoma volume was measured ultrasonografically and the volume change was calculated. Immunohistochemical detection of estrogen receptor (ER), progesterone receptor (PR), bcl-2 and p53 were performed on leiomyoma tissue samples from group A, group B and the matched-control group. H-scores for ER, PR, bcl-2 and p53 were calculated. The mean volume changes of leiomyomas and immunohistochemical H-score differences of ER, PR, bcl-2 and p53 were compared between groups. Results: The leiomyoma volume decreased significantly after treatment in gosereline group from baseline of 65 cm 3 to 35 cm 3 , and in raloxifene group from 68 cm 3 to 50 cm 3 , p < 0.05. The difference between the before and after treatment leiomyoma volumes between the two treatments was not statistically significant. H-score of ER expression was significantly lower in gosereline group compared to control group (54.4 versus 113.2, p = 0.001), whereas H-score of PR expression was significantly lower with both gosereline and raloxifene groups compared to control group (64.8 for gosereline versus 94.6 for control, 73.6 for raloxifene versus 94.6 for control, p = 0.001). The bcl-2 expression was higher in both gosereline and raloxifene groups compared to control group (173.7 for gosereline versus 94.7 for control, 179.7 for raloxifene versus 94.7 for control, p = 0.001). The p53 expression was only lower with gosereline than the control group (169.4 versus 205.6, p = 0.001), whereas there was no significant change between the raloxifene group and the control group (201.9 versus 205.6) (p > 0.05). Conclusion: Raloxifene was as effective as gosereline in reducing leiomyoma volumes. Decreased PR expression may be a mechanism for tumor growth reduction in raloxifene treatment. In both treatment modalities, the mechanism of shrinkage of leiomyomas could not be increased apoptosis mediated by bcl-2 and p53 expression and should be investigated by further studies. © 2006 Elsevier Ireland Ltd. All rights reserved.